- Hand-foot Syndrome Due to Capecitabine
-
Choi CW, Huh CH
- KMID: 2302592
- Korean J Dermatol.
- 2005 Jul;43(7):965-968.
Hand-foot syndrome, also known as acral erythema, is a distinctive and relatively common toxic reaction due to some anticancer drugs. It is characterized by a painful erythema on the palms... -
- CITED
-
- Close
- SHARE
-
- Close
- Hand-Foot Syndrome with Nail Changes Induced by Fluorouracil
-
Kang HA, Park HJ, Kim HO, Kim JW
- KMID: 2303291
- Korean J Dermatol.
- 2000 Apr;38(4):546-548.
Many chemotherapeutic agents induce both local and systemic cutaneous toxicity. Among them, Fluorouracil (5-FU) induces various cutaneous reaction, including hand-foot syndrome, hypersensitivity, hyperpigmentation and nail changes. We describe a male... -
- CITED
-
- Close
- SHARE
-
- Close
- Differential Diagnosis between Hand-foot Syndrome and Gout in Colorectal Cancer with Capecitabine: A Case Study and Review of the Literature
-
Park JY
- KMID: 2269468
- Asian Oncol Nurs.
- 2014 Mar;14(1):1-6.
- doi: 10.5388/aon.2014.14.1.1
PURPOSE: This study is to present a case of a patient experiencing foot pain after being prescribed capecitabine and to review the differential diagnosis between hand-foot syndrome and gout. METHODS: This... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Hand-Foot Syndrome with Pustules and Paronychia Induced by Sunitinib
-
Choi JW, Kim SW, Woo SM, Won CH, Cho S
- KMID: 2248073
- Korean J Dermatol.
- 2008 Oct;46(10):1384-1386.
In January 2006, Sunitinib was approved by the US Food and Drug Administration for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumor. Sunitinib inhibits the receptor tyrosine... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Hand-Foot Syndrome Induced by Sunitinib
-
Jeong JS, Yun JH, Yoon SJ, Kim WJ, Lee JY, Yoon TY
- KMID: 1484230
- Korean J Dermatol.
- 2008 Sep;46(9):1236-1239.
Sunitinib (SU11248) is a novel orally administered small molecule that inhibits multiple receptor tyrosine kinases so that can block tumor growth and angiogenesis. It was approved on 2006, for the... -
- CITED
-
- Close
- SHARE
-
- Close
- Mizoribine Induced Hand-Foot Syndrome
-
Hong JW, Jeon SY, Lee KY, Lee CY, Kim KH, Kim YH
- KMID: 2301880
- Korean J Dermatol.
- 2010 Jul;48(7):642-645.
Hand-foot syndrome is also known as palmar-plantar erythrodysesthesia, and it is a side effect that mostly occurs with chemotherapy or biologic therapy. It is characterized by a painful erythema and... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Bullous Fixed Drug Eruption Coexisting with Hand-Foot Syndrome and This Was Induced by Sunitinib
-
Jeong TJ, Lee EJ, Jeong KH, Shin MK, Kim NI
- KMID: 2247829
- Korean J Dermatol.
- 2009 Jun;47(6):739-742.
Sunitinib is multitargeted tyrosine kinase inhibitor, and this drug was approved for use to treat gastrointestinal stromal tumor and advanced renal cell carcinoma. It has also been shown to be... -
- CITED
-
- Close
- SHARE
-
- Close
- Skin-Related Toxicity of Tyrosine Kinase Inhibitor in Thyroid Cancer
-
Lim DJ
- KMID: 2448976
- Int J Thyroidol.
- 2018 Nov;11(2):82-87.
- doi: 10.11106/ijt.2018.11.2.82
Skin-related toxicity is one of the most important adverse events from multi-target tyrosine kinase inhibitor (MTKI) to treat radioiodine refractory thyroid cancer. As hand foot skin reaction can limit quality... -
- CITED
-
- Close
- SHARE
-
- Close
- Hand-foot Syndrome Following Capecitabine (Xeloda(R)) Monotherapy for Colorectal Cancer
-
Park SD, Lee KY, Park SJ, Lee SH, Lee SM
- KMID: 2334441
- J Korean Soc Coloproctol.
- 2009 Aug;25(4):227-233.
PURPOSE: Capecitabine (Xeloda(R)), which is a systemic prodrug of 5-fluorouracil, can be used in oral formulation for treatment of advanced colorectal cancer as a 1st line or an alternative modality... -
- CITED
-
- Close
- SHARE
-
- Close
- Hand-Foot syndrome induced by sorafenib, a multitargeted tyrosine kinase inhibitor, in a patient with advanced renal cell carcinoma
-
Lee SH, Noh SH, Kim SY, Jang KY, Hwang PH
- KMID: 2037347
- Korean J Pediatr.
- 2009 Jan;52(1):119-123.
- doi: 10.3345/kjp.2009.52.1.119
Renal cell carcinoma (RCC) arising from epithelial cells of the renal tubules is a highly aggressive and malignant tumor in all ages; however, it rarely occurs in children. the standard... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Dermatologic Diseases in Patients Receiving Anticancer Treatments: A Retrospective Study of 140 Cases
-
Kang JN, Kim DH, Seol JE, Jung SY, Wang HY, Kim H
- KMID: 2371079
- Korean J Dermatol.
- 2017 Feb;55(2):89-95.
BACKGROUND: A number of anticancer agents are known to induce many adverse reactions in the skin. Related cutaneous adverse drug reactions influence the morbidity, mortality, and anti-cancer regimen of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation
-
Kim MJ, Kim HJ, Bae HM, Sim SH, Lee JO, Cha Y, Lee SH
- KMID: 2258140
- Korean J Med.
- 2009 Aug;77(Suppl 1):S188-S191.
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib.... -
- CITED
-
- Close
- SHARE
-
- Close
- Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K)
-
Nam SH, Choi HJ, Kang WD, Kim SM, Lim MC, Park SY, Kim JS, Kim BG, Bae DS, Lee JW, Kim TJ, Song T
- KMID: 2355627
- J Korean Med Sci.
- 2016 Dec;31(12):1969-1975.
- doi: 10.3346/jkms.2016.31.12.1969
Given the growing number of cancer patients and the resulting increase in the administration of chemotherapeutic agents, convenient and effective methods for measuring the symptoms and quality of life associated... -
- CITED
-
- Close
- SHARE
-
- Close
- Low Dose Methotrexate induced Bullous Acral Erythema in a Child with Acute Lymphoblastic Leukemia
-
Cho SY, Lee JH
- KMID: 2279830
- Clin Pediatr Hematol Oncol.
- 2014 Oct;21(2):168-171.
- doi: 10.0000/cpho.2014.21.2.168
Chemotherapy-induced acral erythema (CIAE) is an uncommon, self-limited local skin reaction that usually occurs after high-dose chemotherapy. There is no specific treatment for this disease and it disappears within three... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Leukocytoclastic Vasculitis after Use of Sorafenib (Nexavar(R))
-
Kim HJ, Kim JH, Kim JB, Kim HK, Ko YS, Joh OJ, Lee JS, Song KY
- KMID: 2248297
- Korean J Dermatol.
- 2008 May;46(5):648-651.
Sorafenib (Nexavar(R)) is an oral multikinase inhibitor that was recently approved for use in metastatic renal cancer. It is currently undergoing investigation for the treatment of locally advanced renal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- A New Option for Advanced Gastric Cancer: Docetaxel and Novel Oral Fluoropyrimidine Combination Chemotherapy
-
Zang DY
- KMID: 2184865
- J Korean Med Assoc.
- 2007 Jun;50(6):556-560.
- doi: 10.5124/jkma.2007.50.6.556
Although gastric cancer is the most common cancer and the second leading cause of cancer deaths in Korea, the prognosis for advanced gastric cancer remains poor, and there is no... -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience
-
Lee YJ, Kim YM, Lee SW, Park JY, Kim DY, Suh DS, Kim JH, Kim YT, Nam JH
- KMID: 2393842
- Obstet Gynecol Sci.
- 2017 Sep;60(5):433-439.
- doi: 10.5468/ogs.2017.60.5.433
OBJECTIVE: This study aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) with or without carboplatin in Korean patients with recurrent ovarian cancer (ROC), fallopian tube, or... -
- CITED
-
- Close
- SHARE
-
- Close
- Drug Eruption
-
Choi YW
- KMID: 2283996
- Ewha Med J.
- 2012 Sep;35(2):76-82.
- doi: 10.12771/emj.2012.35.2.76
Drug eruptions are common problems in hospital inpatients and outpatients. Cutaneous drug reactions range from mild to severe and from those localized only to skin to those associated with systemic... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
-
Choi JG, Seo JH, Oh SC, Choi CW, Kim JS
- KMID: 2167598
- Cancer Res Treat.
- 2012 Jun;44(2):127-132.
PURPOSE: The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. MATERIALS AND METHODS: Patients with advanced... -
- CITED
-
- Close
- SHARE
-
- Close
- Scrotal Erythema Associated with Sorafenib Therapy in a Patient with Hepatocellular Carcinoma
-
Ryu HR, Yun CH, Kim JH, Choi JS, Lee JR, Roh JY, Baek JO
- KMID: 2350794
- Korean J Dermatol.
- 2016 Feb;54(2):136-140.
Sorafenib is an oral, multi-targeted tyrosine kinase inhibitor with anti-angiogenic and anti-proliferative activity. It is approved for the treatment of unresectable hepatocellular and advanced renal carcinomas. Cutaneous toxicity is relatively... -
- CITED
-
- Close
- SHARE
-
- Close
